English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

While new options of treatment and management of inflammatory bowel disease (IBD) are being continuously explored [1-3], the introductions of biological products such as infliximab and adalimumab, both of which are tumour necrosis factor (TNF)alpha inhibitors, have indeed provided therapeutic options for many IBD patients.4 The likely introductions of other biosimilar versions of both infliximab and adalimumab are expected to bring down the cost of therapy and be more affordable for larger pool of IBD patients [4].

Use of Vitamin D3 in Inflammatory Bowel Disease (IBD) Patients: The Ongoing Saga